Fujifilm (TSE:4901) has reportedly spent big to double the size of its United Kingdom-based vaccine manufacturing facility.
The Financial Times reported that Fujifilm is spending about $532.8 million (£400 million) to expand its Teesside (north-east England) plant that is making the Novavax COVID-19 vaccine, transforming it with factories specializing in antibody treatments and viral gene therapies.
Get the full story at our sister site, Pharmaceutical Processing World.
Fujifilm (TSE:4901) has reportedly spent big to double the size of its United Kingdom-based vaccine manufacturing facility.
The Financial Times reported that Fujifilm is spending about $532.8 million (£400 million) to expand its Teesside (north-east England) plant that is making the Novavax COVID-19 vaccine, transforming it with factories specializing in antibody treatments and viral gene therapies.
According to the report, builders have already begun construction on one facility, while the land for the other remains undeveloped to this point. FT said the facilities are set to open in 2023 with up to 350 highly skilled jobs to be created in contract manufacturing.
Fujifilm manufactures the active ingredient for the vaccines developed by Novavax, FT said. Novavax’s vaccine was recently submitted to regulators, according to the report, but has not received approval in the UK, while the company said months ago that it intended to file for FDA emergenc…
Fujifilm Medical Systems U.S.A. and Fujifilm Healthcare Americas announced last week that the two companies have merged.
Now operating under the name Fujifilm Healthcare Americas Corporation, the new combination of organizations aims to bring together the strengths of each company’s product portfolios and employees to create new value for customers and advance medical care, according to a news release.
Henry Izawa will serve as president & CEO, with an executive management team including chairman Jun Higuchi, SVP of modality solutions John Hahn, SVP of medical informatics Bill Lacy, SVP of sales Jason Heim, SVP of regulatory & quality affairs Randy Vader, VP of endoscopy Taisuke Fujita and VP of the office of the president & CEO Takehiro Fujimoto.
“We have built a new foundation leveraging the strengths of each organization to demonstrate the clinical value and relevance of our combined portfolio,” Izawa said in the release. “Integratin…
Fujifilm Medical Systems has been awarded a long-term sole-source contract from the U.S. government for its digital radiography (DR) systems.
Lexington, Massachusetts-based Fujifilm confirmed last month that the U.S. Navy and Defense Logistics Agency (DLA) awarded it the 10-year contract to outfit Naval Fleet vessels with its DR x-ray room systems.
Fujifilm’s DR x-ray room systems include next-generation detector technology and a high-quality, compact, floor-mounted room with all of the latest features. The company anticipates the initial DR system delivery and installation will occur for a new U.S. navy ship later this year.
The Navy selected Fujifilm’s DR system on the back of a two-year evaluation and comparison with competitive technologies. The company was selected as the singular vendor that best met or exceeded the Navy’s standards and criteria, it said.
“Fujifilm is honored to be awarded this significant contract from the…
Fujifilm (TSE:4901) today announced that it received CE mark approval for its antigen test kit to detect COVID-19.
The rapid diagnostic test detects SARS-CoV-2 infection. It uses the company’s silver application immunochromatography method that is based on silver amplification technology used in the photo developing process.
Fujifilm said that the antigen test is highly sensitive with the silver amplification immunochromatography method and can rapidly detect the presence of COVID-19 at an early stage and in a view of a relatively low viral load.
“During the pandemic, Fujifilm supported the global healthcare community in the complex management of the emergency,” Masaharu Fukumoto, senior VP of Fujifilms medical systems division, said in a news release. “It did so through its diagnostic and IT/AI solutions so that COVID-19 patients could be treated with the utmost care and precision. Today we can provide further support for the ear…
Johnson & Johnson, Steris, Philips, Fujifilm Holdings and Boston Scientific were recently named among Forbes’ best large employers in America, based on feedback from their employees.
Forbes partnered with a market research firm to survey 50,000 Americans working for businesses with at least 1,000 employees. Survey participants were asked to rate their willingness to recommend their employer to friends and family and to nominate a business that wasn’t their own.
Get the full story on our sister site, Medical Design & Outsourcing.
Fujifilm Diosynth Biotechnologies announced that its College Station, Texas, site will manufacture a COVID-19 vaccine candidate under a $265 million federal contract.
The contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies said it received the federal task order through the Texas A&M System Center for Innovation in Advanced Development & Manufacturing (CIADM), a public-private partnership between the government’s Biomedical Advanced Research and Development Authority (BARDA) and the university. CIADM subcontracts manufacturing to the Fujifilm Diosynth Biotechnologies’ owned-and-operated flexible biomanufacturing facility in College Station. The task order reserves manufacturing at the plant capacity in through the end of 2021.
The money will help accelerate Fujifilm Diosynth’s planned facility expansion by several months, now with an anticipated completion by fall 2020. The Texas…